Brazil to produce measles and rubella vaccine for poor countries

RIO DE JANEIRO Mon Oct 28, 2013 5:51pm IST

Brazil's Minister of Health Alexandre Padilha reacts after a conference for foreign doctors at the University of Brasilia August 26, 2013. REUTERS/Ueslei Marcelino

Brazil's Minister of Health Alexandre Padilha reacts after a conference for foreign doctors at the University of Brasilia August 26, 2013.

Credit: Reuters/Ueslei Marcelino

Related Topics

Stocks

   

RIO DE JANEIRO (Reuters) - Brazil´s top biomedical research and development center announced plans on Monday to produce a combined measles and rubella vaccine for developing countries, mainly in Africa.

The first Brazilian vaccine developed specifically for export will be made by Bio-Manguinhos, a unit of the Oswaldo Cruz Foundation (Fiocruz), in partnership with the Bill & Melinda Gates Foundation.

Brazilian health minister Alexandre Padilha announced the vaccine plan at a medical science conference that the Gates Foundation organized in Rio de Janeiro.

Brazil is following other leading emerging nations such as China and India in investing in biomedical technology to supply vaccines and medicines to developing countries at lower costs than those produced by pharmaceutical industries in developed nations.

Measles kills 158,000 people a year in the world, mostly children under the age of five. Rubella, a contagious viral disease with symptoms like mild measles, can cause serious consequences to pregnant women and their babies.

Bio-Manguinhos, which has a track record of making combined measles, mumps and rubella vaccines, will produce 30 million doses per year of the new measles/rubella vaccine to supply developing countries in Africa, Asia and Latin America.

This will increase the availability of a vaccine that today is produced by only one manufacturer, the Serum Institute of India Ltd.

The Gates Foundation said it would grant $1.1 million to support clinical trials and might contribute additional funds in subsequent phases of the project.

Bio-Manguinhos has been producing the combined measles, mumps and rubella vaccine since 2003 under a technology transfer agreement with GlaxoSmithKline Plc. This triple vaccine is used in Brazil´s immunization program, but was not adopted in many developing countries due to its cost and the limited epidemiological presence of mumps in a number of them.

The new measles/rubella vaccine is aimed at that group of nations and is expected to reach the market by 2017.

(Reporting by Anthony Boadle; Editing by Lisa Von Ahn)

FILED UNDER:

REUTERS EXCLUSIVE

Reuters Showcase

Documentary Banned

Documentary Banned

Documentary on 2012 Delhi gang rape banned in India.  Full Article 

RBI Rate Cut

RBI Rate Cut

RBI surprises with post-budget rate cut.  Full Article 

Beef Ban

Beef Ban

After beef ban, Hindu groups force abattoirs to close   Full Article 

Insurance Reforms

Insurance Reforms

Opposition support bolsters prospects for insurance reforms.  Full Article 

Axed by Censors

Axed by Censors

India's censor blocks 'Fifty Shades of Grey' from cinemas.  Full Article 

Bollywood Focus

Bollywood Focus

Franchise Man swoops in to save Bollywood.  Full Article 

Reuters Exclusive

Reuters Exclusive

India expects better monsoon rains this year.  Full Article 

Reuters Interview

Reuters Interview

Budget lacks wow, but good enough: Jim O’Neill.  Full Article 

Slim Chances

Slim Chances

Dozens of miners missing, feared dead after blast in east Ukraine.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage